Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Telisotuzumab adizutecan with or without osimertinib versus standard of care in previously treated EGFR-mutated advanced non-squamous non-small cell lung cancer
NL-OMON59184Phase 3Recruiting
- Sponsor
- AbbVie Inc.
- Start
- Mar 2026
- Modality
- Small Molecules, Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3 trial of telisotuzumab adizutecan and osimertinib in non-small cell lung cancer (NSCLC) (3 arms), sponsored by AbbVie Inc. Primary endpoints: Objective response, Progression-free survival and 2 more. Started Mar 2026; status: recruiting.
02
Drugs
telisotuzumab adizutecanosimertinib
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NL-OMON59184.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON59184.